BioSpace News Archive

Mediar Therapeutics announced Simon Sturge has joined the firm as executive chairman.

Unicycive Therapeutics, Inc., a clinical stage biotechnology company developing therapies for patients with kidney disease, announced the Company is scheduled to be added as a member of the Russell Microcap® Index as part of the 2021 Russell indexes reconstitution after the market opens on September 20, 2021, based on a preliminary list of additions.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced that it will hire and train a 15-person oncology sales force to supplement the Boehringer Ingelheim oncology commercial team.

Clinical collaboration to assess HB-200 in combination with KEYTRUDA ® (pembrolizumab) as first-line treatment HOOKIPA poised to advance clinical development program with randomized Phase 2 study in 2022

Ms. Barnett brings a wealth of financial experience to Immunovant Expands executive leadership team as Immunovant plans to return to the clinic across multiple indications

Magenta Therapeutics, Inc. announced today that its Investigational New Drug (IND) application for MGTA-117 is active with the U.S. Food and Drug Administration (FDA).

Oramed Pharmaceuticals Inc. announced today that it has enrolled over 50% of patients planned for its Phase 2 trial of its oral insulin capsule ORMD-0801 for the treatment of non-alcoholic steatohepatitis (NASH).

Cyclo Therapeutics, Inc. today announced that N. Scott Fine, Chief Executive Officer and Sharon Hrynkow, PhD, Chief Scientific Officer and Senior Vice President for Medical Affairs of Cyclo Therapeutics, will present at the virtual Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 22, 2021 at 10:45 AM ET.

PhaseBio Pharmaceuticals, Inc. today announced the appointment of William D. Humphries to its board of directors.

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced that the group has received clearance from the US FDA regarding the IND application to initiate clinical trials of SACT-1, an orally administered repurposed small molecule drug for the treatment of neuroblastoma.